Important Information for Maravai Lifesciences Holdings, Inc. (MRVI) Investors: Rosen Law Firm Announces Deadline for Lead Plaintiff in Securities Class Action Lawsuit
New York, NY – April 02, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024, and February 24, 2025 (the “Class Period”), of the important May 5, 2025, lead plaintiff deadline. The lawsuit alleges that Maravai Lifesciences Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that:
- The Company was experiencing declining sales in its key product lines;
- The Company’s financial statements for the fiscal year 2024 contained material errors;
- The Company’s internal controls over financial reporting were weak;
- The Company’s revenue growth was a result of acquisitions and not organic growth;
On February 25, 2025, Maravai Lifesciences Holdings, Inc. announced its financial results for the fourth quarter and fiscal year 2024. The Company reported a net loss for the fiscal year 2024, which was significantly larger than the net income reported in the previous fiscal year. Following this announcement, the Company’s stock price declined significantly.
Impact on Individual Investors
If you purchased Maravai Lifesciences Holdings, Inc. securities during the Class Period, you may be entitled to compensation without having to file an individual lawsuit. The lead plaintiff will act on behalf of all other class members in managing the litigation. If you wish to join the lawsuit, you can provide your information by contacting Phillip Kim, Esq. of Rosen Law Firm at 484-275-4090 or via email at [email protected]. You may also submit your information using the form on the firm’s website at www.rosenlegal.com/cases-register/maravai-lifesciences-holdings-inc.
Impact on the World
The lawsuit against Maravai Lifesciences Holdings, Inc. highlights the importance of accurate financial reporting and strong internal controls. Companies that fail to provide truthful and transparent financial information can face significant consequences, including reputational damage, regulatory scrutiny, and financial losses for investors. This case serves as a reminder for all publicly traded companies to prioritize the accuracy and transparency of their financial reporting.
Conclusion
Rosen Law Firm encourages investors who purchased Maravai Lifesciences Holdings, Inc. securities during the Class Period to contact the firm before the May 5, 2025, lead plaintiff deadline. The firm is dedicated to ensuring that investors receive the compensation they deserve, and the lead plaintiff will act on behalf of all class members in managing the litigation. For more information about the class action lawsuit against Maravai Lifesciences Holdings, Inc. or to join the case, investors are encouraged to contact Phillip Kim, Esq. of Rosen Law Firm at 484-275-4090 or via email at [email protected].
About Rosen Law Firm
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The firm was Ranked No. 1 in 2015 for both the number of cases on behalf of investors and the total dollar amount recovered through settlements and judgments in securities class actions. For more information about the firm, please visit www.rosenlegal.com.
